CRISPR/Cas9-based therapeutics (INSERM/Genethon/Stanford university)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCRISPR/Cas9-based therapeutics (INSERM/Genethon/Stanford university)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant proteinSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionHemoglobin beta chain modulators
TargetsHemoglobin beta chain
Therapy Area/Indicationsbeta-ThalassemiaAnemia, Sickle Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesInstitut National De La Sante Et De La Recherche Medicale
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInstitut National De La Sante Et De La Recherche MedicaleGenethonStanford University
Active IndicationsN/A
Inactive Indicationsbeta-ThalassemiaAnemia, Sickle Cell

Other Information

ATC CodeN/A
Related LinksN/A